A PTPRZ1 monoclonal antibody and its application
By modifying hiPSCs with the CAR gene, antibodies that specifically bind to PTPRZ1 and chimeric antigen receptors were prepared, solving the problem of limited treatment efficacy for malignant gliomas and achieving precision treatment of gliomas.
Patent Information
- Application Number
- CN202611559166.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2026-06-12
- Filing Date
- 2026-10-09
- Publication Date
- 2026-11-17
AI Technical Summary
Current technologies lack effective targeted therapies for the PTN-PTPRZ1 signaling axis, resulting in limited treatment outcomes for malignant gliomas and an urgent need for novel targeted therapy strategies.
By modifying hiPSCs with the CAR gene to express chimeric antigen receptor macrophages (CAR-M) that can recognize PTPRZ1, the aim is to achieve precise recognition, killing, or phagocytosis of malignant glioma cells. Antibodies or antigen-binding fragments that specifically bind to PTPRZ1 are prepared, and chimeric antigen receptors are constructed and introduced into induced pluripotent stem cells.
It provides new targeted drugs and methods, improves the treatment effect of glioma, and achieves precise identification and killing of malignant glioma cells, breaking through the limitations of existing treatments.
Smart Images

Figure CN123106908A_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of biomedical technology, specifically relating to a PTPRZ1 monoclonal antibody and its applications. Background Technology
[0002] Gliomas are the most common primary neuroepithelial tumors in adults. Malignant gliomas are characterized by high rates of disability and recurrence, severely impacting patients' quality of life. Current treatment options for malignant gliomas primarily involve surgery, supplemented by radiotherapy and temozolomide chemotherapy, but the therapeutic effects are quite limited. There is an urgent need to study the regulatory mechanisms of glioma biological behavior and develop novel treatment strategies based on this understanding.
[0003] PTN (pleiotrophin) is a pleiotropic growth factor that is secreted extracellularly and regulates various biological functions such as cell proliferation, migration, and angiogenesis by binding to its receptor PTPRZ1 (Protein Tyrosine Phosphatase Receptor-type Z-polypeptide 1). Studies have shown that overactivation of the PTN-PTPRZ1 signaling pathway promotes the rapid proliferation, invasion, and migration of GBM, and currently, there are no effective therapeutic measures targeting the PTN-PTPRZ1 signaling axis.
[0004] Chimeric antigen receptor (CAR) technology is a technique that uses genetic engineering to enable immune cells to express CARs. CARs typically contain a single-chain variable region fragment capable of specifically recognizing tumor-associated antigens, a transmembrane domain, and an intracellular signaling domain, thereby endowing immune cells such as T cells and macrophages with the ability to specifically recognize, kill, or engulf tumor cells. The single-chain variable region fragment is usually formed by connecting the heavy chain variable region (VH) and light chain variable region (VL) of tumor antigen-reactive antibodies via a flexible linker. CAR-T cell therapy has made progress in the treatment of some hematologic malignancies, but it still faces challenges in the treatment of solid tumors.
[0005] Human induced pluripotent stem cells (hiPSCs) are stem cells obtained by introducing transcription factors into adult cells and reprogramming them. They possess both unlimited proliferative capacity and the ability to differentiate in vitro into various terminally functional cells such as macrophages and NK / T cells. Macrophages, as important members of the tumor microenvironment, have the potential to regulate immune responses and directly phagocytose tumor cells.
[0006] Based on the current treatment needs of malignant gliomas, hiPSCs can be genetically modified to express a single-chain variable region fragment that can recognize PTPRZ1, and differentiated in vitro into chimeric antigen receptor macrophages (CAR-M) with the ability to target and recognize PTPRZ1, so as to achieve precise recognition, killing or phagocytosis of malignant glioma cells; this is of great significance for breaking through the limitations of existing treatments and developing new targeted therapy technologies. Summary of the Invention
[0007] In order to more effectively prevent and treat gliomas and meet the needs of glioma patients for new drugs, the present invention provides the following technical solutions.
[0008] In a first aspect, the present invention provides an antibody or antigen-binding fragment that specifically binds to PTPRZ1, wherein the antibody or antigen-binding fragment comprises CDR1, CDR2, and CDR3 of the heavy chain variable region and CDR1, CDR2, and CDR3 of the light chain variable region.
[0009] Preferably, the amino acid sequences of the antibody heavy chain variable regions CDR1, CDR2, and CDR3 are as shown in SEQ ID NO.1, 2, and 3, respectively; and the amino acid sequences of the antibody light chain variable regions CDR1, CDR2, and CDR3 are as shown in SEQ ID NO.4, 5, and 6, respectively.
[0010] Specifically, the amino acid sequences of SEQ ID NO.1-6 are as follows: GYTMN (SEQ ID NO.1); LINPYNGVTYYNQKFKV(SEQ ID NO.2); CRGLRGFDY (SEQ ID NO.3); QATQDIVENLN(SEQ ID NO.4); YATELAE (SEQ ID NO.5); LQFYEFPRT (SEQ ID NO.6).
[0011] Preferably, the amino acid sequence of the heavy chain variable region is as shown in SEQ ID NO.7 or has more than 85% identity with it.
[0012] Preferably, the amino acid sequence of the light chain variable region is as shown in SEQ ID NO.8 or has more than 85% identity with it.
[0013] Furthermore, the amino acid sequences of SEQ ID NO.7-8 are as follows: EVQLQQSGPELVKPGASMKISCKASGYSFTGYTMNWVKQSHGKNLEWIGLINPYNGVTYYNQKFKVKATLTVDKSSSTAYMELLSLTSEDSAVYYCARCRGLRGFDYWGQGTTLTVSS (SEQ ID NO. 7).
[0014] EIQMTQSPSSMSASLGDRITITCQATQDIVENLNWYQQKPGKPPSFLIYYATELAEGVPSRFSGSGSGSDYSLTISNLESEDFADYYCLQFYEFPRTFGGGTKLEIK (SEQ ID NO. 8).
[0015] Preferably, the coding sequence of the heavy chain variable region is as shown in SEQ ID NO.9 or has more than 85% identity with it.
[0016] Preferably, the coding sequence of the light chain variable region is as shown in SEQ ID NO.10 or has more than 85% identity with it.
[0017] Furthermore, the nucleic acid sequences of SEQ ID NO. 9-10 are as follows: GAGGTCCAGCTGCAACAGTCTGGACCTGAACTGGTGAAGCCTGGAGCTTCAATGAAGATATCCTGCAAGGCTTCTGGTTACTCATTCACTGGCTACACCATGAACTGGGTGAAGCAGAGCCATGGAAAGAACCTTGAGTGGATTGGACTTATTAATCCTTACAATGGTGTTACTTACTA CAACCAGAAGTTCAAGGTCAAGGCCACATTAACTGTAGACAAGTCATCCAGCACAGCCTACATGGAGCTCCTCAGTCTGACATCTGAGGACTCTGCAGTCTATTACTGTGCAAGATGTAGAGGTTTACGAGGATTTGACTACTGGGGCCAAGGCACCACTCTCACAGTCTCCTCA (SEQ ID NO.9).
[0018] GAAATCCAGATGACCCAGTCTCCATCCTCTATGTCTGCATCTCTGGGAGACAGAATAACCATCACTTGCCAGGCAACTCAAGACATTGTTGAGAATTTAAACTGGTATCAGCAGAAACCAGGGAAACCCCTTTCATTCCTGATCTATTATGCAACTGAACTG GCAGAAGGGGTCCCATCAAGGTTCAGTGGCAGTGGGTCTGGGTCAGACTATTCTCTGACAATCAGCAACCTGGAGTCTGAAGATTTTGCAGACTATTACTGTCTACAGTTTTATGAGTTTCCTCGGACGTTCGGTGGAGGCACCAAGCTGGAAATCAAA (SEQ ID NO.10).
[0019] Furthermore, the aforementioned 85% or more of identity refers to at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, and 99% of identity.
[0020] Preferably, the amino acid sequence of the variable region of the antibody or antigen-binding fragment that specifically binds to PTPRZ1 is as follows: EIQMTQSPSSMSASLGDRITITCQATQDIVENLNWYQQKPGKPPSFLIYYATELAEGVPSRFSGSGSGSDYSLTISNLESEDFADYYCLQFYEFPRTFGGGTKLEIKGGGGSGGGGSGGGGS EVQLQQSGPELVKPGASMKISCKASGYSFTGYTMNWVKQSHGKNLEWIGLINPYNGVTYYNQKFKVKATLTVDKSSSTAYMELLSLTSEDSAVYYCARCRGLRGFDYWGQGTTLTVSS (SEQ ID NO.11).
[0021] Preferably, the coding sequence of the variable region of the antibody or antigen-binding fragment that specifically binds to PTPRZ1 is as follows: (SEQ ID NO.12) In a second aspect, the present invention provides a hybridoma cell containing nucleic acid encoding the antibody or antigen-binding fragment described in the first aspect.
[0022] Preferably, the hybridoma cells express the antibody or antigen-binding fragment described in the first aspect.
[0023] Thirdly, the present invention provides a method for preparing the antibody or antigen-binding fragment described in the first aspect, the method comprising culturing the hybridoma cells described in the second aspect, collecting the culture medium, centrifuging, purifying, and obtaining the antibody or antigen-binding fragment.
[0024] Fourthly, the present invention provides a chimeric antigen receptor comprising the antibody or antigen-binding fragment described in the first aspect.
[0025] Preferably, the chimeric antigen receptor further includes a signal peptide, a tag protein, a linker, a transmembrane domain, and an intracellular signal transduction domain.
[0026] Preferably, the signal peptide includes, but is not limited to, CD8α signal peptide, CD28 signal peptide or GM-CSFR signal peptide, and more preferably CD8α signal peptide.
[0027] Furthermore, the encoding sequence of the CD8αLeader is as follows: ATGGCCTTACCAGTGACCGCCTTGCTCCTGCCGCTGGCCTTGCTGCTCCACGCCGCCAGGCCG (SEQ ID NO. 13).
[0028] Preferably, the tagged protein includes, but is not limited to, MYC, His6, Flag, or HA, and more preferably MYC.
[0029] Furthermore, the encoding sequence of MYC is as follows: GAGCAGAAACTCATCTCTGAAGAGGATCTG (SEQ ID NO. 14).
[0030] Preferably, the connector includes, but is not limited to, CD8αHinge or CD28Hinge, more preferably CD8αHinge.
[0031] Furthermore, the encoding sequence of the CD8αHinge is as follows: ACCACGACGCCAGCGCCGCGACCACCAACACCGGCGCCCACCATCGCGTCGCAGCCCCTGTCCCTGCGCCCAGAGGCGTGCCGGCCAGCGGCGGGGGGCGCAGTGCACACGAGGGGGCTGGACTTCGCCTGTGAT (SEQ ID NO. 15).
[0032] Preferably, the transmembrane domain includes, but is not limited to, the CD28 transmembrane domain or the CD8α transmembrane domain, more preferably the CD28 transmembrane domain. Further, the encoding sequence of the CD28TM is as follows: TTTTGGGTGCTGGTGGTGGTTGGTGGAGTCCTGGCTTGCTATAGCTTGCTAGTAACAGTGGCCTTTATTATTTTCTGGGTGAGGAGTAAGAGGAGCAGGCTCCTGCACAGTGACTACATGAACATGACTCCCCGCCGCCCCGGGCCCACCCGCAAGCATTACCAGCCCTATGCCACCACCACGCGACTTCGCAGCCTATCGCTCC (SEQ ID NO. 16).
[0033] Preferably, the intracellular signal transduction domain includes, but is not limited to, CD3zeta or FcRγ, more preferably CD3zeta.
[0034] Furthermore, the encoding sequence of CD3zeta is as follows: AGAGTGAAGTTCAGCAGGAGCGCAGACGCCCCCGCGTACCAGCAGGGCCAGAACCAGCTCTATAACGAGCTCAATCTAGGACGAAGAGAGGAGTACGATGTTTTGGACAAGAGACGTGGCCGGGACCCTGAGATGGGGGGAAAGCCGAGAAGGAAGAACCCTCAGGAAGG CCTGTACAATGAACTGCAGAAAGATAAGATGGCGGAGGCCTACAGTGAGATTGGGATGAAAGGCGAGCGCCGGAGGGGCAAGGGGCACGATGGCCTTTACCAGGGTCTCAGTACAGCCACCAAGGACACCTACGACGCCCTTCACATGCAGGCCCTGCCCTCGC (SEQ ID NO.17).
[0035] Fifthly, the present invention provides a nucleic acid molecule that encodes the antibody or antigen-binding fragment described in the first aspect or the chimeric antigen receptor described in the fourth aspect.
[0036] In a sixth aspect, the present invention provides a recombinant vector comprising the nucleic acid molecule described in the fifth aspect.
[0037] Preferably, the recombinant vector includes, but is not limited to, plasmids, viruses, and bacteriophages.
[0038] Furthermore, the recombinant vector is pCAR-M.
[0039] Furthermore, the pCAR-M is constructed using the pAAVD-AAVS1(HA)-Ubc-P2A-BFP-Wpre-PolyA(sgDocut)-SaCas9 vector as a backbone, with the encoding DNA of CD8αLeader-PTPRZ1-scFv-MYC-CD8αHinge-CD28TM-CD3zeta inserted after the Ubc promoter.
[0040] In a seventh aspect, the present invention provides a host cell comprising the recombinant vector described in the sixth aspect.
[0041] Preferably, the host cells include, but are not limited to, HEK293T cells, 293 cells, 293T cells, 293FT cells, SW480 cells, u87MG cells, HOS cells, COS1 cells or COS7 cells, and more preferably 293T cells.
[0042] Eighthly, the present invention provides induced pluripotent stem cells (iPSCs) containing nucleic acids encoding the chimeric antigen receptor described in the fourth aspect.
[0043] Preferably, the induced pluripotent stem cells express the chimeric antigen receptor described in the fourth aspect.
[0044] In a ninth aspect, the present invention provides a medicament comprising the antibody or antigen-binding fragment described in the first aspect, the chimeric antigen receptor described in the fourth aspect, or the induced pluripotent stem cell described in the eighth aspect.
[0045] Preferably, the drug further includes pharmaceutically acceptable excipients.
[0046] Preferably, the drug further includes a pharmaceutically acceptable carrier. More preferably, the carrier includes, but is not limited to, a diluent, binder, humectant, surfactant, lubricant, or disintegrant.
[0047] In a tenth aspect, the present invention provides the use of the antibody or antigen-binding fragment described in the first aspect, the hybridoma cell described in the second aspect, the chimeric antigen receptor described in the fourth aspect, the nucleic acid molecule described in the fifth aspect, the recombinant vector described in the sixth aspect, the host cell described in the seventh aspect, or the induced pluripotent stem cell described in the eighth aspect in the preparation of antitumor drugs.
[0048] Preferably, the tumor is a glioma, lung cancer, renal cell carcinoma, etc.
[0049] The beneficial effects of this invention are: This invention prepares an antibody or antigen-binding fragment that specifically binds to PTPRZ1 and a chimeric antigen receptor containing the antibody or antigen-binding fragment, and then introduces the coding sequence of this chimeric antigen receptor into induced pluripotent stem cells. This invention provides novel targeted drugs and methods for the prevention and / or treatment of gliomas. Attached Figure Description
[0050] Figure 1 The figure shown is a flow cytometry graph of the specific binding rate of PTPRZ1 monoclonal antibody. Figure 2 The image shows the plasmid map of pCAR-M; Figure 3 The image shows the plasmid map of pCAR-M-Δ; Figure 4 The image shows the plasmid map of pB2M-HLA-E; Figure 5 The image shown is a flow cytometry plot of the hiPSC gene editing effect. Figure 6 The image shows a flow cytometry diagram of hiPSC monoclonal sorting. Figure 7 The image shown is a sequence diagram of hiPSC single-clone sorted nanopores. Figure 8 The image shows a flow cytometry diagram of hiPSC-derived CAR-Mφ phagocytic bacteria. Detailed Implementation
[0051] The technical solution of the present invention will be further described below with reference to embodiments and accompanying drawings. The advantages and features of the present invention will become clearer as the description unfolds. However, it should be understood that the embodiments are merely exemplary and do not constitute a limitation on the scope of the present invention.
[0052] It should be noted that, unless otherwise specified, the experimental methods and materials used in the following embodiments are conventional methods and materials in the art. Unless otherwise defined, all scientific and technical terms used in this invention have the same meaning as commonly understood by one of ordinary skill in the art.
[0053] Example 1: Preparation and Sequencing of PTPRZ1 Monoclonal Antibody 1.1 Expression and purification of recombinant PTPRZ1 protein A nucleic acid fragment encoding amino acid positions 26-300 of the human PTPRZ1 gene (UniProtKB: P23471) was selected and cloned into the eukaryotic expression vector pSIN-EF-1a-puro (Shanghai Shengbo Biomedical Co., Ltd.) to obtain a eukaryotic expression plasmid. The expression plasmid was transfected into HEK293 cells and cultured in suspension for 5 days. The cell supernatant was collected by centrifugation, and purified by nickel column affinity purification and anion exchange purification to obtain the target protein (recombinant PTPRZ1 protein).
[0054] 1.2 Mouse Immunization and Antibody Detection Freund's complete adjuvant was mixed and emulsified with an equal volume of the antigen protein (recombinant PTPRZ1 protein) at a concentration of 2 mg / mL. Six- to eight-week-old SPF-grade female BALB / c mice were immunized with the resulting emulsified antigen via paw pad injection, with each mouse receiving 100 μg of the antigen protein. Two weeks after the initial immunization, the antigen protein was emulsified with Freund's incomplete adjuvant (PR40027, Proteintech) and injected again via paw pad injection, with each mouse receiving 100 μg of the antigen protein. Two weeks later, blood was collected via tail vein, and serum was collected by centrifugation. Serum titers were measured using an ELISA kit (E-EL-M0044, Elabscience). Mice with serum titers greater than 80,000 were selected for pre-fusion booster immunization.
[0055] 1.3 B-cell fusion and screening and subcloning of positive hybridoma cells 1.3.1 Preparation of spleen B lymphocyte and SP2 / 0 cell suspensions Female BALB / c mice immunized with recombinant PTPRZ1 protein were euthanized by enucleation and exsanguination. Serum was collected after centrifugation of the ocular blood as a positive control for ELISA. Inguinal lymph nodes were aseptically removed from the mice and washed in a glass dish containing 10 mL of incomplete culture medium (PM150110, Procell), carefully removing surrounding connective and adipose tissue. After changing the glass dish, the spleen was removed, placed in a 200-mesh stainless steel mesh, ground with a syringe plunger, and rinsed with incomplete culture medium to allow spleen cells to pass through the mesh into the solution. The spleen cells were transferred to 10 mL glass centrifuge tubes and centrifuged horizontally at 1500 rpm for 10 min, discarding the supernatant. The cells were washed once with 10 mL of incomplete culture medium using the same method, centrifuged to collect the cell pellet, and then resuspended in 10 mL of incomplete culture medium and mixed thoroughly. The cell count was approximately 1 × 10⁶ cells / mL. 8 Each cell.
[0056] SP2 / 0 cells (CL-0445, Procell) were removed from liquid nitrogen and quickly placed in a 37°C water bath with constant shaking until the cell solution was completely dissolved. The cells were then transferred to 10 mL centrifuge tubes and centrifuged horizontally at 1500 rpm for 10 min. The supernatant was discarded, and the pellet was resuspended in 10 mL of complete culture medium (BMM0002, Abbkine). The cell suspension was transferred to 50 mL culture flasks and incubated at 37°C in a 5% CO2 incubator. After the cells showed good growth, they were screened for one week using 8AG selective medium (PYG0110, Boster, Wuhan). Two days before fusion, cells from one flask were transferred to four flasks. On the day of fusion, the cells were in the logarithmic growth phase, with optimal viability, uniform size, and round, translucent appearance. On the day of fusion, SP2 / 0 cells were gently blown off the tube wall using a bent-tip dropper and collected in centrifuge tubes. After centrifugation, the supernatant was discarded, and the pellet was washed with incomplete culture medium and resuspended in 10 mL of incomplete culture medium. The cells were counted and found to be approximately 5 × 10⁶ cells / mL. 7 indivual.
[0057] 1.3.2 Preparation of feeder cells Unimmunized female rats (SPF grade, SD strain, 8-12 weeks old, N-0001 (female), Lack Jingda) were euthanized by enucleation and bloodletting. The rats were disinfected by immersion in 70% ethanol for 5 min. The rat skin was cut open, the peritoneum was lifted with forceps, and a small incision was made with scissors. Pre-cooled incomplete culture medium was used to flush the peritoneal cavity with a bent-tip dropper, and the wash solution was transferred to a 50 mL centrifuge tube. The peritoneal cavity was flushed three times with incomplete culture medium using the same method. The wash solution was collected, centrifuged horizontally at 1000 rpm for 10 min at room temperature, the supernatant was discarded, and the cells were resuspended in 10 mL of incomplete culture medium and counted.
[0058] 1.3.3 Fusion of myeloma cells and splenic B lymphocytes Before fusion, PEG1450 (PR40010, Proteintech) was preheated in a 37°C incubator, and 1×10⁻⁶ molten silica gel was aspirated. 7 One myeloma cell suspension and 1×10 8A suspension of spleen B lymphocytes was transferred to a 50 mL sterile centrifuge tube. 30 mL of RPMI 1640 medium (PM150110, Procell) was added, and the mixture was thoroughly combined. The tube was centrifuged at 1500 rpm for 10 min. The supernatant was discarded, and the bottom of the tube was gently tapped to loosen the cell clumps into a paste. The centrifuge tube was then incubated at 37°C. Using a dropper, 0.8 mL of pre-warmed 50% PEG 1450 solution was slowly added to the cells along the tube wall, approximately 2 cm from the bottom, while rotating the tube. The addition was completed in about 1 min, and the tube was allowed to stand for 90 s. Then, 30 mL of pre-warmed RPMI 1640 medium (37°C) was added dropwise to terminate confluence, completing the addition within 3 min, starting slowly and gradually increasing the speed, using gentle movements. Incubate the centrifuge tubes at 37°C for 5 min, then centrifuge at 1500 rpm for 5 min. Discard the supernatant, resuspend the cells in 10 mL of HAT medium (PR40011, Proteintech), and gently pipette to mix. Seed the confluent cells into 96-well cell culture plates pre-coated with feeder cells at a seeding rate of 100 μL / well. Leave 6 wells on each plate for seeding SP2 / 0 cells as a negative control for HAT selection. Incubate at 37°C in a 5% CO2 incubator.
[0059] Cell growth can be observed under an inverted microscope on day 45 after fusion, and 100 μL of HAT medium can be added. Hybridoma titer can be measured by indirect ELISA on days 10-12, and HAT medium can be used for culture on days 14-15.
[0060] 1.3.4 Screening for specific hybridoma cells Preliminary screening: 12-15 days post-fusion, when cells reached 1 / 4 to 1 / 2 of the wells, the culture supernatant was analyzed using a free ELISA method to screen for positive clones. The microplate was coated with goat anti-mouse polyclonal antibody (0.5 μg / well) and incubated overnight at 4°C. It was washed five times with washing buffer for 5 min each time, the liquid was blotted dry, and 50 μL of cell culture supernatant and 50 μL of 0.2% PBST (P1031, Solarbio) were added. Mouse immune serum was used as the positive control, SP2 / 0 culture supernatant as the negative control, and washing buffer was used as the blank control. The plates were incubated at 37°C for 1 h. Recombinant PTPRZ1 protein was biotinylated to obtain PTPRZ1 biotin. After washing the microplate, 100 μL of PTPRZ1 biotin dilution buffer (approximately 0.5 μg / mL) was added, and the plates were incubated at 37°C for 1 h. After washing the microplate, streptavidin HRP diluted 1:5000 was added, and the plates were incubated at 37°C for 30 min. Wash and pat dry. Add freshly prepared TMB solution at 100 μL / well and react at room temperature in the dark for 35 min. Add 50 μL of stop solution to each well to stop the reaction. Measure the absorbance at 450 nm using a microplate reader.
[0061] 1.3.5 Review and Screening Cellular ELISA was used for retesting and screening. The colorimetric values (OD) in section 1.3.4 were selected. 450 Cell wells >0.5 mm were used for re-selection; the remaining cell wells were discarded. Glioblastoma spherocytes were cultured in 96-well cell culture plates, approximately 4 × 10⁶ cells / well. 4 Cells per well were cultured overnight in an adherent manner. The next day, the culture medium was aspirated, and the cells were washed twice with PBS and fixed with 4% PFA for 10 min. The fixative was aspirated, and the cells were washed twice with PBS. 50 μL of the cell supernatant to be tested was added to each ELISA well and incubated at 300 rpm for 1 h at room temperature. The supernatant was aspirated, and the cells were washed twice with washing buffer. After drying, 1:5000 dilution of HRP-labeled goat anti-mouse polyclonal antibody was added, and the cells were incubated at 300 rpm for 1 h at room temperature. After washing and drying, 100 μL of freshly prepared TMB solution was added per well, and the reaction was incubated in the dark at room temperature for 35 min. 50 μL of stop solution was added per well to terminate the reaction, and the absorbance at 450 nm was measured using a microplate reader. Cells with a colorimetric value >0.3 were selected for subsequent clonal culture.
[0062] The results showed that by immunizing six female Balb / c mice with recombinant PTPRZ1 protein as the antigen and performing two fusions, a total of five hybridoma cell lines capable of secreting high-affinity PTPRZ1 antibodies were obtained. After three cloning and ELISA screenings, hybridoma cell lines secreting PTPRZ1 monoclonal antibodies were obtained. These hybridoma cells were cryopreserved several times and cultured in vitro for more than three months, and were able to stably secrete PTPRZ1 monoclonal antibodies. Finally, they were cryopreserved in liquid nitrogen.
[0063] 1.4 Antibody purification and preparation The selected and cloned hybridoma cells were expanded and cultured, then seeded into shake flasks for serum-free culture medium (SF3001, Procell) for fermentation. The fermentation was carried out at a rate of 1×10⁻⁶. 6 Inoculate shake flasks with a concentration of [number] cells / mL and incubate continuously at 37℃ and 65 rpm under aseptic conditions for 4 days. After fermentation, collect the culture medium, centrifuge at 15℃ and 4000 g for 30 min, collect the supernatant, and filter the supernatant through a 0.45 μm filter membrane. Collect the filtrate and perform affinity purification using a protein G purification column to obtain the target antibody.
[0064] 1.5 Identification of antibody subtypes and cloning of gene sequences 1.5.1 The SBA Clonotyping System HRP kit from Southern Biotech was used to identify the heavy and light chain isotypes of the monoclonal antibody according to the instructions.
[0065] The specific procedure is as follows: Dilute the capture antibody to 1 μg / mL with coating buffer (0.05M pH=9.5 carbonate and bicarbonate buffer), add 100 μL / well to the microplate, and incubate overnight at 4°C. Wash the plate three times with PBS buffer containing 0.05% Tween 20 (wash buffer). Dilute the culture supernatant of the hybridoma cells to be tested 1:1 with diluent (1% BSA, 0.1% PBST), add 100 μL / well to the microplate, and incubate at 37°C for 30 min. Dilute the corresponding enzyme-labeled antibodies (IgHRP, IgG1HRP, IgG2aHRP, IgG2bHRP, IgG3HRP, IgMRP, kappaHRP, lambdaHRP) at a dilution of 1:3000 with diluent. After washing the plate three times with wash buffer, add 100 μL of diluted enzyme-labeled antibody to each well and incubate at 37°C for 30 min. After washing the plate three times, the chromogenic solution was added. The reaction was stopped after approximately 5 minutes (depending on the reaction strength) by adding 2 M sulfuric acid, and the absorbance was read at 450 nm. Five monoclonal antibodies were identified: 18C5 antibody, 12B9 antibody, 24A7 antibody, 8H4 antibody, and 5D12 antibody. All five monoclonal antibodies had IgG2a heavy chains and Kappa light chains.
[0066] 1.5.2 Based on the antibody subtype results, clone the antibody gene sequence.
[0067] The specific procedure is as follows: collect hybridoma cells in good growth condition, extract total RNA from hybridoma cells using Thermo's TRIzol, reverse transcribe the mRNA into cDNA according to Takara's PrimeScript II Reverse Transcriptase instructions, and store at -20°C for later use.
[0068] The specific reverse transcription procedure is as follows: First, prepare a 10 μL premix of template RNA / primer DNA, including 1 μL of 10 μM reverse transcription primer (Oligo d(T)18Primer), 4 μL of 2.5 mM dNTP mixture, and 5 μL of RNA (total less than 5 μg). After mixing, incubate at 65°C for 5 min and immediately place on ice. Add 4 μL of 5×PrimeScript II buffer, 20 units of RNase inhibitor, and 1 μL of Primer Script II RTase (200 units) to the premix. After mixing, incubate at 42°C for 60 min, then at 70°C for 15 min, and finally cool on ice for later use.
[0069] Using cDNA as a template, antibody gene amplification primers reported in the literature "Sequencing and cloning of antigen-specific antibodies from mouse memory B cells" (Nature Protocols, 2016 Oct, 11(10):1908-1923, doi:10.1038 / nprot.2016.102) were used for amplification, and primers capable of efficiently amplifying antibody genes were screened. PCR was performed according to the Phanta Max Super-Fidelity DNA Polymerase instructions from Nanjing Novizan Pharmaceutical Co., Ltd.
[0070] The PCR reaction system consisted of: 25 μL 2×Phanta, 1 μL dNTP, 4 μL 10 μM primer pair, 4 μL hybridoma cell cDNA, 1 μL DNA polymerase, and 15 μL dd H2O, with a total reaction volume of 50 μL.
[0071] The amplification conditions were as follows: pre-denaturation 94℃, 3 min; denaturation 94℃, 30 s; annealing 56℃, 30 s; extension 72℃, 2 min. The PCR products were recovered from the gel according to the OMEGA Gel Extraction Kit instructions. The amplified products were ligated into the T vector, and the antibody gene sequence was obtained by plasmid sequencing.
[0072] 1.6 Flow cytometry detection of antibody binding specificity 1) Use 18C5 antibody, 12B9 antibody, 24A7 antibody, 8H4 antibody and 5D12 antibody as primary antibodies, with a final concentration of 1 μg / mL, and incubate on ice for 30 min. 2) Wash once with PBS; 3) Alexa Fluor 647 fluorescent secondary antibody (A-31571, Invitrogen), diluted 1:1000, incubated on ice for 20 min; 4) Wash twice with PBS and then perform flow cytometry.
[0073] The specific binding rates of 18C5 antibody, 12B9 antibody, 24A7 antibody, 8H4 antibody and 5D12 antibody were analyzed by flow cytometry.
[0074] like Figure 1As shown, the positive rates of 18C5 antibody, 12B9 antibody, 24A7 antibody, 8H4 antibody, and 5D12 antibody were 80.1%, 68.9%, 58.7%, 49.1%, and 50.8%, respectively. The specific binding rate of 18C5 antibody was significantly higher than that of the other antibodies. Therefore, 18C5 antibody was selected for subsequent experiments.
[0075] The heavy chain variable region CDR1-3 and light chain variable region CDR1-3 of the 18C5 antibody were numbered using the Kabat numbering system. The specific amino acid sequences are as follows: Heavy chain variable region CDR1: GYTMN (SEQ ID NO.1); Heavy chain variable region CDR2: LINPYNGVTYYNQKFKV (SEQ ID NO.2); Heavy chain variable region CDR3: CRGLRGFDY (SEQ ID NO.3); Light chain variable region CDR1: QATQDIVENLN (SEQ ID NO.4); Light chain variable region CDR2: YATELAE (SEQ ID NO.5); Light chain variable region CDR3: LQFYEFPRT (SEQ ID NO.6).
[0076] The amino acid sequence of the variable region of the 18C5 antibody heavy chain is as follows: EVQLQQSGPELVKPGASMKISCKASGYSFTGYTMNWVKQSHGKNLEWIGLINPYNGVTYYNQKFKVKATLTVDKSSSTAYMELLSLTSEDSAVYYCARCRGLRGFDYWGQGTTLTVSS (SEQ ID NO. 7).
[0077] The amino acid sequence of the variable region of the 18C5 antibody light chain is as follows: EIQMTQSPSSMSASLGDRITITCQATQDIVENLNWYQQKPGKPPSFLIYYATELAEGVPSRFSGSGSGSDYSLTISNLESEDFADYYCLQFYEFPRTFGGGTKLEIK (SEQ ID NO. 8).
[0078] The coding sequence of the variable region of the 18C5 antibody heavy chain is as follows: GAGGTCCAGCTGCAACAGTCTGGACCTGAACTGGTGAAGCCTGGAGCTTCAATGAAGATATCCTGCAAGGCTTCTGGTTACTCATTCACTGGCTACACCATGAACTGGGTGAAGCAGAGCCATGGAAAGAACCTTGAGTGGATTGGACTTATTAATCCTTACAATGGTGTTACTTACTACAACCAGAAGTTCAAGGTCAAGGCCACATTAACTGTAGACAAGTCATCCAGCACAGCCTACATGGAGCTCCTCAGTCTGACATCTGAGGACTCTGCAGTCTATTACTGTGCAAGATGTAGAGGTTTACGAGGATTTGACTACTGGGGCCAAGGCACCACTCTCACAGTCTCCTCA (SEQ ID NO.9).
[0079] The coding sequence of the 18C5 antibody light chain variable region is as follows: GAAATCCAGATGACCCAGTCTCCATCCTCTATGTCTGCATCTCTGGGAGACAGAATAACCATCACTTGCCAGGCAACTCAAGACATTGTTGAGAATTTAAACTGGTATCAGCAGAAACCAGGGAAACCCCCTTCATTCCTGATCTATTATGCAACTGAACTGGCAGAAGGGGTCCCATCAAGGTTCAGTGGCAGTGGGTCTGGGTCAGACTATTCTCTGACAATCAGCAACCTGGAGTCTGAAGATTTTGCAGACTATTACTGTCTACAGTTTTATGAGTTTCCTCGGACGTTCGGTGGAGGCACCAAGCTGGAAATCAAA (SEQ ID NO.10).
[0080] The amino acid sequence of the 18C5 antibody is as follows: EIQMTQSPSSMSASLGDRITITCQATQDIVENLNWYQQKPGKPPSFLIYYATELAEGVPSRFSGSGSGSDYSLTISNLESEDFADYYCLQFYEFPRTFGGGTKLEIKGGGGSGGGGSGGGGSEVQLQQSGPELVKPGASMKISCKASGYSFTGYTMNWVKQSHGKNLEWIGLINPYNGVTYYNQKFKVKATLTVDKSSSTAYMELLSLTSEDSAVYYCARCRGLRGFDYWGQGTTLTVSS (SEQ ID NO.11).
[0081] The coding sequence of 18C5 antibody is as follows: (SEQ ID NO.12).
[0082] Example 2: Determination of Affinity of PTPRZ1 Monoclonal Antibody The affinity of 18C5 antibody, 12B9 antibody, 24A7 antibody, 8H4 antibody and 5D12 antibody for recombinant PTPRZ1 antigen protein was determined by SPR binding assay.
[0083] Prepare the run buffer (0.01 M HEPES, 0.15 M NaCl, 3 mM EDTA, 0.05% Tween-20, pH=7.4) and connect the run buffer reagent bottle to the Biacore T200 (GE Healthcare). Place the CM5 chip in the chip compartment and run the Primer program to flush the system tubing. Dilute Anti-Mouse IgG 20-fold with 10 mM sodium acetate buffer (pH=5.0) and load it into an EP tube. Separately load the amino-coupling reagents into an EP tube, place it on the reagent rack, and put it into the Biacore T200 sample compartment. Run the manual program to perform the three steps of chip activation, ligand conjugation, and blocking in sequence, covalently conjugating Anti-Mouse IgG to the four channels of the CM5 chip.
[0084] Dilute the ligand (recombinant PTPRZ1 antigen protein from 1.1) and analytes (5 PTPRZ1 monoclonal antibodies) to the target concentrations (5 nM, 10 nM, 20 nM, 40 nM, 80 nM, 160 nM) using HEPES running buffer. Load the ligand and analytes into EP tubes and place them on the reagent rack; load the 10 mM glycine regeneration buffer (pH=1.7) into EP tubes and place them on the reagent rack. Place the reagent rack into the Biacore T200 sample chamber, open the affinity assay program, select channels "2-1, 3-1, 4-1" for the chip flow path, and use a multi-cycle kinetic method (setting parameters: capture channels 2 / 3 / 4, flow rate 10 μL / min, capture time 45 s; analyte channels 1, 2, 3, 4, flow rate 30 μL / min, injection time 120 s, dissociation time 900 s; regeneration solution flow rate 30 μL / min, regeneration time 90 s). Set the chip chamber and sample chamber temperature to 25℃, and determine the affinity between the analyte and ligand. Analyze the kinetic data using a 1:1 binding model.
[0085] Table 1 Results of PTPRZ1 antibody affinity assay As shown in Table 1, the KD values of the five PTPRZ1 antibodies are all in the range of 10^-8 M. Among them, the KD value of PTPRZ1 antibody (18C5) is 1.82×10^-8 M, which is lower than that of the other four PTPRZ1 antibodies, indicating that the 18C5 antibody has a higher affinity among the candidate antibodies in this group.
[0086] Example 3 Construction of a universal anti-PTPRZ1 chimeric antigen receptor-associated plasmid 3.1 CAR Vector Construction according to Figure 2 and Figure 3Construct plasmids with PTPRZ1 recognition target (pCARM) and plasmids without PTPRZ1 recognition target (pCARMΔ).
[0087] Furthermore, the pCAR-M is constructed using the pAAVD-AAVS1(HA)-Ubc-P2A-BFP-Wpre-PolyA(sgDocut)-SaCas9 vector as a backbone, with the encoding DNA (SEQ ID NO. 20) of CD8αLeader-PTPRZ1-scFv-MYC-CD8αHinge-CD28TM-CD3zeta inserted after the Ubc promoter. The pCARMΔ is constructed using the pAAVD-AAVS1(HA)-Ubc-P2A-BFP-Wpre-PolyA(sgDocut)-SaCas9 vector as a backbone, with CD8αLeaderMYCCD8αHingeCD28TM... The CD3zeta encoding DNA (SEQ ID NO.19) was constructed by inserting it into the Ubc promoter.
[0088] The DNA encoding CD8αLeader (the signal peptide that guides CAR protein expression to the cell membrane) is as follows: ATGGCCTTACCAGTGACCGCCTTGCTCCTGCCGCTGGCCTTGCTGCTCCACGCCGCCAGGCCG (SEQ ID NO. 13).
[0089] The DNA encoding MYC (tag protein) is as follows: GAGCAGAAACTCATCTCTGAAGAGGATCTG (SEQ ID NO. 14).
[0090] The DNA encoding CD8αHinge (linker) is as follows: ACCACGACGCCAGCGCCGCGACCACCAACACCGGCGCCCACCATCGCGTCGCAGCCCCTGTCCCTGCGCCCAGAGGCGTGCCGGCCAGCGGCGGGGGGCGCAGTGCACACGAGGGGGCTGGACTTCGCCTGTGAT (SEQ ID NO. 15).
[0091] The DNA encoding CD28TM (transmembrane domain) is as follows: TTTTGGGTGCTGGTGGTGGTTGGTGGAGTCCTGGCTTGCTATAGCTTGCTAGTAACAGTGGCCTTTATTATTTTCTGGGTGAGGAGTAAGAGGAGCAGGCTCCTGCACAGTGACTACATGAACATGACTCCCCGCCGCCCCGGGCCCACCCGCAAGCATTACCAGCCCTATGCCCCACCACGCGACTTCGCAGCCTATCGCTCC (SEQ ID NO.16).
[0092] The encoding DNA of CD3zeta (intracellular signal transduction domain) is as follows: AGAGTGAAGTTCAGCAGGAGCGCAGACGCCCCCGCGTACCAGCAGGGCCAGAACCAGCTCTATAACGAGCTCAATCTAGGACGAAGAGAGGAGTACGATGTTTTGGACAAGAGACGTGGCCGGGACCCTGAGATGGGGGGAAAGCCGAGAAGGAAGAACCCTCAGGAAGGCCTGTACAATGAACTGCAGAAAGATAAGATGGCGGAGGCCTACAGTGAGATTGGGATGAAAGGCGAGCGCCGGAGGGGCAAGGGGCACGATGGCCTTTACCAGGGTCTCAGTACAGCCACCAAGGACACCTACGACGCCCTTCACATGCAGGCCCTGCCCCCTCGC (SEQ ID NO.17).
[0093] The encoding DNA of CD8αLeaderMYCCD8αHingeCD28TMCD3zeta is as follows: atggccttaccagtgaccgccttgctcctgccgctggccttgctgctccacgccgccaggccgGAGCAGAAACTCATCTCTGAAGAGGATCTGaccacgacgccagcgccgcgaccaccaacaccggcgcccaccatcgcgtcgcagcccctgtccctgcgcccagaggcgtgccggccagcggcggggggcgcagtgcacacgagggggctggacttcgcctgtgatttttgggtgctggtggtggttggtggagtcctggcttgctatagcttgctagtaacagtggcctttattattttctgggtgaggagtaagaggagcaggctcctgcacagtgactacatgaacatgactccccgccgccccgggcccacccgcaagcattaccagccctatgccccaccacgcgacttcgcagcctatcgctccagagtgaagttcagcaggagcgcagacgcccccgcgtaccagcagggccagaaccagctctataacgagctcaatctaggacgaagagaggagtacgatgttttggacaagagacgtggccgggaccctgagatggggggaaagccgagaaggaagaaccctcaggaaggcctgtacaatgaactgcagaaagataagatggcggaggcctacagtgagattgggatgaaaggcgagcgccggaggggcaaggggcacgatggcctttaccagggtctcagtacagccaccaaggacacctacgacgcccttcacatgcaggccctgccccctcgc (SEQ ID NO. 19).
[0094] The coding DNA of CD8αLeader PTPRZ1 scFvMYCCD8αHingeCD28TMCD3zeta is as follows:
[0095] 3.2 Construction of vectors with B2M knockout and HLA-E knock-in 1) Based on the "universal" hiPSC line construction protocol, using pAAVD-B2M(HA600)-E2A-mNeonGreen-Wpre-pA(sgDocut) as the vector, HLA-E was knocked into the stop codon of B2M to express the B2M-HLA-E fusion gene, thereby knocking out the B2M gene to avoid the risk of immune rejection caused by HLA-I molecules, while retaining the HLA-E structure to avoid NK cell killing caused by the complete absence of HLA-I molecules. Based on this, a plasmid (pB2M-HLA-E) was constructed with B2M knockout and HLA-E knock-in. Figure 4 ).
[0096] The coding DNA of the HLA-E fragment knocked into the endogenous B2M stop codon and fused in situ with the endogenous B2M coding region is as follows: 2) PCR identification primers for the B2M(HA)-GS-HLA-E-mNeonGreen and AAVS1(HA)-PTPRZ-CAR-BFP insert fragments were designed. The primer sequence for the B2M site was B2M-R:TGTCACCCCAACTATGCCATTTAAC (SEQ ID NO.21), and the primer sequence for the AAVS1 site was AAVS1-FBC:TGCAAACAGGAAGTGAACGG (SEQ ID NO.22). The size of the knock-in fragment was detected by gel electrophoresis, and the correctness of the vector sequence was further confirmed by vector sequencing.
[0097] Example 4: hiPSC gene editing, electroporation into plasmid, and detection of its expression. The experimental procedure is as follows.
[0098] 1) Prepare two hiPSC (BC1) target cells in advance, and use Plasmocin at a final concentration of 25 μg / mL. TM After two weeks of prophylactic (InvivoGen, ant-mpt) treatment, when the hiPSC clones have grown to the point of just contact, single-cell passages were performed using Accutase, and 5 μM Y27632 was added and seeded into new Matrigel-coated culture plates. 2) Prepare 10 μg spCas9V3 (Integrated DNA Technologies, 1081059) + 180 pmolsg131 (BR530, Fenghui Biotechnology), incubate at room temperature for 10-60 min, and prepare two RNPs. Before electroporation, add them together with 0.5 μg pCDNA3.1-Myc-BioID2-MCS mammalian cell plasmid (Shanghai Yaji Biotechnology Co., Ltd., YS-1933F) to the electroporation buffer. 3) hiPSCs were electroporated using a 1.0M Nucleofection program, the Human Stem Cell Nucleofector™ Kit2 (Lonza, VPI-1002), and 70 μL of TransIT®-LT1 (Mirus Bio, MIR2300). After electroporation, 500 μL of culture medium (containing 10 μM Y27632) was added and transferred to new Matrigel-coated 24-well plates. The medium was replaced with fresh medium after 4-8 hours. 4) One to two days after electroporation, the expression of BFP and mNeonGreen fluorescence in the mixed cell line was detected by flow cytometry to evaluate the gene editing effect of hiPSC.
[0099] like Figure 5As shown in the flow cytometry analysis of the B2M-WT-AAVS1(HA)-WT (negative control), B2M-HLA-E-mNeonGreen-AAVS1(HA)-BFP, and B2M-HLA-E-mNeonGreen-AAVS1(HA)-PTPRZ1-CAR-BFP mixed cell lines, it can be seen that gene editing was successfully performed in both mixed cell lines, with the two-site insertion (BFP) being particularly successful. + mNeonGreen + The proportions of the positive control cells were 34% and 18%, respectively, while the proportion of the negative control cells B2M-WT-AAVS1(HA)-WT was 0%.
[0100] Example 5: hiPSC monoclonal flow cytometry sorting and sequencing 5.1 Single Clonal Sorting and Amplification 1) The gene-edited hiPSC hybrid cell line was kept in a 37°C, 5% CO2 incubator and cultured in mTeSR1 medium to the appropriate density, and then passaged and expanded (crystallized backup cells were stored). B2M-WT-AAVS1(HA)-WT (negative control), B2M-HLA-E-mNeonGreen-AAVS1(HA)-BFP, and B2M-HLA-E-mNeonGreen-AAVS1(HA)-PTPRZ1-CAR-BFP were cultured simultaneously.
[0101] 2) Gene-edited hiPSC hybrids were treated with Accutase digestive enzymes to form single-cell suspensions. Individual hiPSCs were sorted by flow cytometry and seeded into new Matrigel-coated 96-well plates. Microscopic examination ensured that each well contained only one cell.
[0102] 3) Continue to culture single-cell clones in a 37℃, 5% CO2 incubator for clonal expansion and cryopreservation, and regularly observe cell growth and morphology to ensure that they maintain hiPSC characteristics.
[0103] 5.2 Monoclonal Flow Cytometry Detection 1) Two days in advance, hiPSC monoclonal antibodies were treated with 25 ng / mL IFNγ to induce mNeonGreen fluorescence expression.
[0104] 2) Digest hiPSC monoclonal cells into single cells using Accutase, centrifuge at 1200 rpm for 5 min and discard the supernatant. Resuspend the cells in 1 mL PBE (containing 2% FBS and 0.5 mM EDTA) and filter out adherent cells using a 100 μm cell filter. Divide the cells into three portions and transfer them to flow cytometry tubes.
[0105] 3) The fluorescence expression of BFP and mNeonGreen was detected using a BD Canto II flow cytometer, and the data were analyzed using Flowjo software.
[0106] like Figure 6 The flow cytometry results shown are for B2M-WT-AAVS1(HA)-WT (negative control), B2M-HLA-E-mNeonGreen-AAVS1(HA)-BFP, and B2M-HLA-E-mNeonGreen-AAVS1(HA)-PTPRZ1-CAR-BFP positive monoclonal strains. This indicates the double-positive expression rate of the two positive monoclonal strains (BFP...). + mNeonGreen + The proportion of B2M-WT-AAVS1(HA)-WT cells was close to 100%, while the proportion of negative control cells was 0%.
[0107] 5.3 Monoclonal Nanopore Sequencing 1) Genomic DNA was extracted after hiPSC monoclonal amplification, and the DNA concentration and purity were determined using a UV spectrophotometer.
[0108] 2) Prepare DNA fragments suitable for Nanopore sequencing and ligate sequencing aptamers so that DNA molecules can pass smoothly through the nanopore.
[0109] 3) Prepare the sequencing chip (Flow Cell) and ensure that the nanopores are active. Load the required sequencing reagents and buffers according to the requirements of the NativeBarcoding Kit 96 V14 kit (Nanopore, SQK-NBD114.96).
[0110] 4) Start the nanopore sequencer and deliver the library to the chip via an automated fluid system. As the DNA molecules pass through the nanopore, record the changes in current as they pass through the pore in real time and analyze the current signals in real time to determine the nucleotide sequence.
[0111] 5) Perform quality control and filtering on the collected sequencing data, use sequence assembly and annotation software to process and analyze the data, and identify and analyze features such as variations and repetitive sequences in the DNA sequence.
[0112] like Figure 7 The representative nanopore sequencing results of the two inserted fragments at the B2M and AAVS1 sites shown indicate that the B2M site gene was successfully knocked out and the PTPRZ1-CAR at the AAVS1 site was successfully knocked in.
[0113] Example 6: Preparation and Verification of Phagocytic Function of hiPSC-derived CAR-Mφ 6.1 Differentiation and Acquisition of iPSC-derived CAR-Mφ 1) Embryomorph (EB) formation and mesodermal induction (Day 0-Day 4): On Day 0, the gene-edited hiPSCs were digested into single cells and cultured in suspension on mTeSR1 medium (STEMCELL Technologies, 85850) to promote embryomorph formation. Subsequently, 10 ng / mL BMP4 and 5 ng / mL bFGF were added sequentially to Stempro-34 SFM differentiation medium (Gibco, 10639011) to drive the cells to transform into mesoderm and early hematopoietic endothelium.
[0114] 2) Expansion of hematopoietic progenitor cells (Day 4-Day 7): Replace the differentiation medium with Stempro-34 SFM and add a complex of cytokines including 5 ng / mL bFGF, 15 ng / mL VEGF, 10 ng / mL IL-6, 5 ng / mL IL-11, 25 ng / mL IGF-1, 50 ng / mL LSCF, 30 ng / mL TPO, 10 ng / mL Flt-3 and 30 ng / mL IL-3 to expand hematopoietic stem / progenitor cells in large quantities.
[0115] 3) EB Dissociation and Precursor Cell Harvesting (Day 12-Day 14): All EBs were collected, dissociated using Accutase digestion solution (Sigma-Aldrich, A6964), and filtered into a single-cell suspension. Cells were then seeded into Stemspan SFEM medium (STEMCELL Technologies, 09650) containing 25 ng / mL IL-3 and 50 ng / mL M-CSF for adherent culture. Once the bottom adherent cell layer matured, the large number of released suspension precursor cells were harvested from the culture dishes during Day 12-Day 14.
[0116] 4) Terminal maturation and maintenance: The collected precursor cell pellet was resuspended in Stemspan SFEM medium containing only 50 ng / mL M-CSF and cultured for a longer period. The cells will reattach and exhibit the typical microphenotype of mature cells.
[0117] 6.2 Opsonization 1) Remove the fluorescently labeled E. coli particles and sonicate for 3-5 minutes to break up the agglomerates.
[0118] 2) Use 10% human serum (Complement Technology, Catalog # NHS) as the conditioning solution. Resuspend the bacteria in PBS containing 10% human serum and incubate at 37°C for 30 min.
[0119] 3) Transfer the mixture to a 15 mL centrifuge tube, centrifuge and wash to remove free serum, and adjust the bacterial concentration to 2 × 10⁻⁶ using HBSS (Gibco, 14175-095). 7 / mL.
[0120] 6.3 Phagocytosis Co-incubation and Fluorescence Quenching Reaction 1) Discard the culture medium and use pre-cooled PBS containing 2 mM EDTA with a cell scraper to gently obtain iPSC-derived CAR-Mφ that adheres to the cell wall, minimizing the shedding of surface receptors such as CD14 and CAR.
[0121] 2) Set the multiplicity of infection (MOI) of bacteria to cells to 20:1, and mix about 1×10^5 iPSC-derived CAR-Mφ with the conditioned E. coli in a 15 mL centrifuge tube.
[0122] 3) Incubate the mixture at 37°C for 1 hour in the dark.
[0123] 4) After incubation, immediately place on ice and add pre-cooled PBS to a 15 mL centrifuge tube to wash and centrifuge to terminate phagocytosis.
[0124] 5) Quenching treatment: Resuspend the cell pellet in quenching buffer containing Trypan Blue and incubate on ice in the dark for 5 minutes to completely quench the fluorescent bacterial signals that have not been engulfed into the cell and are only attached to the cell surface.
[0125] 6.4 Termination, identification of live and dead cells, surface staining, and full-spectrum flow cytometry analysis 1) After quenching, add pre-cooled FACS buffer and wash and centrifuge in a 15 mL centrifuge tube to remove residual quenching agent.
[0126] 2) Resuspend the cells in 100 μL FACS buffer, add APC-Cy7 labeled CD14 antibody, and incubate at 4°C in the dark for 30 min.
[0127] 3) After washing twice with pre-cooled PBS, resuspend the cells in 300 μL of PBS before instrumentation. Five minutes before instrumentation, add an appropriate amount of DAPI (dye for identifying live and dead cells) to the cell suspension.
[0128] 4) Use an Aurora Cytometer to analyze and acquire multicolor fluorescence signals.
[0129] like Figure 8 The iPSC-derived CAR-Mφ shown can phagocytose fluorescent Escherichia coli conditionated with human serum. By introducing a quenching process and removing dead and live cells, false positives caused by extracellular nonspecific adhesion and dead cell adsorption were effectively eliminated, confirming that the prepared iPSC-derived CAR-Mφ possesses specific biological phagocytic function.
[0130] Example 7: Validation of tumor phagocytic capacity of hiPSC-derived CAR-Mφ The experimental procedure and results are as follows.
[0131] 7.1 Obtaining hiPSC-derived CAR-Mφ Following the experimental steps of Example 6, hiPSC-derived CAR-Mφ were differentiated.
[0132] 7.2 hiPSC-derived CAR-Mφ was co-cultured with PTPRZ1-positive tumor cells (4201HUM-CCTCC00093, China Center for Type Culture Collection (CCTCC)).
[0133] 1) Plate the differentiated hiPSC-derived CAR-Mφ: discard the supernatant, wash once with PBS, digest with Accutase enzyme, centrifuge at 800 g, discard the supernatant after 5 min; 2) Add medium containing 20 ng / mL M-CSF, count the cells, and seed them at 1×10^5 cells per well in a 96-well ultra-low adhesion plate, 100 μL per well, and incubate overnight; 3) Digest and stain PTPRZ1-overexpressing tumor cells: Resuspend PTPRZ1-overexpressing cells in 500 μL of starting solvent, add 2.5 μL of PKH26 dye, and incubate at 37°C for 15 min; 4) Add 5 mL of serum to stop staining, mix well, centrifuge, discard the supernatant, resuspend the cells in serum-containing culture medium, count, wash, and centrifuge at 300 g for 5 min. 5) Resuspend the cells in serum-free RPMI-1640 medium to 2×10^5 cells / 100 μL, add to 96-well plates, and incubate at 37°C for 4 h.
[0134] 7.3 Flow cytometry detection of the phagocytic capacity of hiPSC-derived CAR-Mφ The phagocytic capacity of hiPSC-derived CAR-Mφ for tumor cells was detected using flow cytometry. The detection indicators were L / D ratio (live / dead), tumor cell PKH26, and macrophage CD11b. The results showed that the CAR-M group transfected with a single-stranded variable region fragment containing anti-PTPRZ1 significantly increased the proportion of phagocytosed tumor cells with high PTPRZ1 expression compared to the CAR-M-Δ group without this single-stranded variable region fragment. This indicates that the anti-PTPRZ1 chimeric antigen receptor constructed in this invention can significantly increase the phagocytic ratio of human macrophages by binding to PTPRZ1 on tumor cells.
[0135] The preferred embodiments of the present invention have been described in detail above. However, the present invention is not limited to the specific details in the above embodiments. Within the scope of the technical concept of the present invention, various simple modifications can be made to the technical solution of the present invention, and these simple modifications all fall within the protection scope of the present invention.
Claims
1. An antibody or antigen-binding fragment that specifically binds to PTPRZ1, characterized in that, The antibody or antigen-binding fragment includes CDR1, CDR2, and CDR3 of the heavy chain variable region and CDR1, CDR2, and CDR3 of the light chain variable region; The amino acid sequences of the variable regions CDR1, CDR2, and CDR3 of the antibody heavy chain are shown in SEQ ID NO.1, 2, and 3, respectively. The amino acid sequences of the variable regions CDR1, CDR2, and CDR3 of the antibody light chain are shown in SEQ ID NO.4, 5, and 6, respectively.
2. The antibody or antigen-binding fragment according to claim 1, characterized in that, The amino acid sequence of the heavy chain variable region is shown in SEQ ID NO.7; the amino acid sequence of the light chain variable region is shown in SEQ ID NO.
8.
3. A hybridoma cell, characterized in that, The hybridoma cells contain nucleic acids encoding the antibody or antigen-binding fragment of any one of claims 1-2.
4. A chimeric antigen receptor, characterized in that, The chimeric antigen receptor comprises the antibody or antigen-binding fragment of any one of claims 1-2.
5. A nucleic acid molecule, characterized in that, The nucleic acid molecule encodes any of the antibodies or antigen-binding fragments described in claims 1-2 or the chimeric antigen receptor described in claim 4.
6. A recombinant vector, characterized in that, The recombinant vector comprises the nucleic acid molecule of claim 5.
7. A host cell, characterized in that, The host cell comprises the recombinant vector of claim 6.
8. An induced pluripotent stem cell, characterized in that, The induced pluripotent stem cells contain nucleic acids encoding the chimeric antigen receptor of claim 4.
9. A drug, characterized in that, The drug comprises any of the antibodies or antigen-binding fragments of claims 1-2, the chimeric antigen receptor of claim 4, or the induced pluripotent stem cells of claim 8.
10. The use of any antibody or antigen-binding fragment of claim 1-2, the hybridoma cell of claim 3, the chimeric antigen receptor of claim 4, the nucleic acid molecule of claim 5, the recombinant vector of claim 6, the host cell of claim 7, or the induced pluripotent stem cell of claim 8 in the preparation of antitumor drugs.
